Ben Hohl

Ben is the Chief Financial Officer at Enliven Therapeutics. Prior to joining Enliven, Ben was a Healthcare Investment Banker at Goldman Sachs, where he worked for nearly a decade. While at Goldman Sachs, he established himself as a senior leader in the healthcare group, advising biopharmaceutical and life sciences management teams and boards and executing a broad range of strategic and financing transactions. Ben successfully executed over 50 deals, including over $75 billion in M&A, equity, and debt financings.

Ben earned a B.A. in Business Economics and Accounting from the University of California, Los Angeles.